异常黑胆质成熟剂合用5-氟尿嘧啶对移植性EAC肿瘤的增效减毒作用

 为探讨异常黑胆质成熟剂对移植性EAC 肿瘤的抑制作用及异常黑胆质成熟剂对5-氟尿嘧啶致毒副作用的保护作用和增效减毒作用，建立了移植性EAC 肿瘤模型，60 只小鼠随机分为正常对照组、肿瘤模型组、5-氟尿嘧啶（5-Fu）对照组、5-FU 联合异黑高剂量组、5-FU 联合异黑中剂量组、5-FU 联合异黑低剂量组6 组，观察小鼠抑瘤率、脾指数、胸腺指数和肝脏指数，小鼠血清中的超氧化物歧化酶（SOD）、丙二醛（MDA）、谷胱甘肽过氧化物酶（GSH-Px）含量的变化。研究结果表明，5-FU 联合异常黑胆质成熟剂高剂量组、5-FU 联合异常黑胆质成熟剂中剂量组、5-FU 联合异常黑胆质成熟剂低剂量组和氟尿嘧啶对照组的抑瘤率分别为42.41%、58.09%，41.58%和50.83%。正常对照组与肿瘤模型组小鼠胸腺质量比、脾脏质量比和肝脏质量比相比，差异有显著性（P<0.05）。与肿瘤模型组比较，5-FU 联合异常黑胆质成熟剂中剂量组、5-FU 联合异常黑胆质成熟剂低剂量组的胸腺质量比均明显降低；与氟尿嘧啶对照组比较，5-FU 联合异常黑胆质成熟剂高剂量组、5-FU 联合异常黑胆质成熟剂中剂量组、5-FU 联合异常黑胆质成熟剂低剂量组的脾脏质量比均明显升高，差异均有显著性（P<0.05）。与肿瘤模型组比较，5-FU 联合异常黑胆质成熟剂高剂量组、5-FU 联合异常黑胆质成熟剂低剂量组的肝脏质量比变化明显，差异均有显著性（P<0.05）。正常对照组与肿瘤模型组小鼠血清中SOD 活性，GSH-Px 活性，MDA 含量相比，差异有显著性（P<0.05）。与肿瘤模型组血清中SOD 活性、GSH-Px 活性比较，5-FU 联合异黑高低剂量组有显著升高，差异均有显著性（P<0.05），其中5-FU 联合异黑中剂量组最高，已接近正常值。与5-FU 对照组血清中SOD 活性、GSH-Px 活性比较，5-FU 联合异常黑胆质成熟剂各剂量组有显著升高，差异均有显著性（P<0.05），其中5-FU 联合异常黑胆质成熟剂中剂量组SOD、GSH-Px 活性最高，已接近正常值。MDA 含量在5-FU 联合异常黑胆质成熟剂中剂量最低，与肿瘤模型组比较有显著降低，差异均有显著性（P<0.05）。异常黑胆质成熟剂具有显著的免疫增强作用，表现在与5-氟尿嘧啶联合用药后对5-氟尿嘧啶所致的免疫功能损伤有保护作用，异常黑胆质成熟剂对移植性肿瘤EAC 肿瘤有较强的增效减毒作用。

Synergistic Attenuation of Abnormal Savda Munziq Combination with 5-Fluorouracil on Transplantated EAC Tumor

This paper studies the inhibitive effect of the abnormal savda munziq on the transplanted EAC tumor and the protective effect of the abnormal savda munziq on 5-fluorouracil-induced toxicity. The 60 transplantated EAC tumor model mice were randomly divided into 6 groups: The normal control group, the tumor control group, the 5-fluorouracil (5-FU) group, the high dose 5-FU ASMq group, the middle dose 5-FU ASMq group, and the low dose 5-FU ASMq group. The content changes of the mouse tumor inhibition rate, the spleen index, the thymus index, and the indices of liver, mouse serum SOD, MDA, GSH-Px were observed. In the 5-FU high-dose ASMq group, the 5-FU medium-dose ASMq group, the 5-FU low-dose ASMq group and the 5-FU group, the values of the tumor inhibition rate were found to be 42.41%, 58.09%, 41.58% and 50.83%, respectively, showing that the tumor function is weakened. Compared with the model group, the thymus/body weight ratio is clearly reduced in the 5-FU medium-dose ASMq group and the 5-FU low-dose ASMq group. Compared with the 5-FU group, the spleen/body weight ratio is clearly increased in the 5-FU high-dose ASMq group, the 5-FU medium-dose ASMq group, and the 5-FU low-dose ASMq group, and the difference was significant (P<0.05). In the 5-FU ASMq dose groups, the levels of SOD and GSH-Px are reduced compared with that in the 5-FU control group, and the difference is significant (P<0.05). In the 5-FU medium-dose ASMq group, the SOD and GSH-Px levels are high. With respect to the MDA values, the 5-FU medium-dose ASMq group has the lowest values and in comparison with the model control group, the difference is significant (P<0.05). With respect to the SOD and GSH-Px levels, compared with the model group, the 5-FU high dose ASMq group has lower levels, and the difference is significant (P<0.05). For the synergy and the attenuation of the abnormal savda munziq combined 5-fluorouracil to the transplanted EAC tumor, abnormal savda munziq dose group, the SOD, GSHPx levels are up to close to normal. The lowest MDA values of the abnormal savda munziq dose group indicate that the combination of the abnormal savda munziq can reduce the toxicity of the 5-fluorouracil portability EAC tumor significantly.